This study validates the pH regulator CAIX as a strong therapeutic candidate with potential effectiveness in treatment of breast cancer, including TNBC, and as far as we are aware, is the first report to show the preclinical efficacy of CAIX inhibition in human breast cancer tissue from various breast cancer subtypes, thus potentially helping to fill critical gaps in breast cancer treatment as previously outlined [1]. Here, CA9 is linked to breast carcinoma.